Physician profile
Bennett Yu
NPI 1609922343
$656.81
in general payments reported to CMS, 2019-2025
16 companies · $169 in 2025
The $169 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.17 · 2020: $249 · 2022: $17.78 · 2024: $146 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $314.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $133.17 | 2020 | |
| Janssen Biotech, INC. | $130.65 | 2020-2025 | Rybrevant, Carvykti, Erleada |
| Rigel Pharmaceuticals, INC. | $121.20 | 2024 | Tavalisse, Rezlidhia |
| Merck Sharp & Dohme LLC | $31.31 | 2019-2020 | |
| Daiichi Sankyo INC. | $27.95 | 2019 | |
| Eisai INC. | $27.91 | 2025 | |
| Tempus Ai, INC | $24.37 | 2024 | |
| Puma Biotechnology, INC. | $23.64 | 2025 | |
| Karyopharm Therapeutics INC. | $23.28 | 2020 | |
| Glaxosmithkline, LLC. | $18.70 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $17.78 | 2022 | |
| Pfizer INC. | $16.96 | 2020 | |
| Legend Biotech USA INC. | $16.67 | 2025 | Carvykti |
| Genzyme Corporation | $14.98 | 2019 | |
| Astellas Pharma US INC | $14.39 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $13.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bennett Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.